A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

1. Participants must be Chinese adult men \>= 18 years of age

2. Participants must have an ECOG performance status of 0 to 1

3. Participant must have histological pathological and/or cytological confirmation of adenocarcinoma of the prostate

4. Participants must be \[68Ga\]Ga-PSMA-11 PET/CT scan positive, and eligible as determined by the sponsor's central reader

5. Participants must have a castrate level of serum/plasma testosterone (\< 50 ng/dl, or \< 1.7 nmol/L)

6. Participants must have progressed only once on prior second generation ARDT (abiraterone, enzalutamide, darolutamide, or apalutamide)) in either HSPC or CRPC setting.

* first generation androgen receptor inhibitor therapy (e.g. bicalutamide) is allowed but not considered as prior ARDT therapy

* second generation ARDT must be the most recent therapy received

7. candidates for change in ARDT (eligible to receive abiraterone or enzalutamide) as assessed by the treating physician

• Participants cannot have previously progressed nor had intolerable toxicity to both enzalutamide and abiraterone

8. Documented progressive mCRPC, based on at least 1 of the following criteria:

* Serum/plasma PSA progression defined as 2 consecutive increases in PSA measured at least 1 week apart. the minimal start value is 2.0 ng/ml;

* Soft-tissue progression defined based on PCWG3-modified RECIST v1.1(Eisenhauer et al 2009, Scher et al 2016)

* Progression of bone disease: two new lesions; only positivity on the bone scan defines metastatic disease to bone (PCWG3 criteria Scher et al 2016)

9. Participants must have at least one metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained =\< 28 days prior to randomization

10. Participants must have adequate organ function:

* Bone marrow reserve:

* ANC \>= 1.5 x 109/L

* Platelets \>= 100 x 109/L

* Hemoglobin \>= 9 g/dL

* Hepatic:

* Total bilirubin \< 2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome =\< 3 x ULN is permitted

* ALT or AST =\< 3.0 x ULN OR =\< 5.0 x ULN for participants with liver metastases

* Albumin \>= 2.5 g/dL

* Renal:

* eGFR \>= 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation

7. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression

8. Cardiac or cardiac repolarization abnormality, including any of the following:

* History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment

* Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block) and QTc\>=500.

9. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation

10. Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: Participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.

What this study is about